- Policy
- 'Rebate points deduction system' has been stalled
- by Lee, Jeong-Hwan Nov 4, 2025 06:13am
- The revision of South Korea's Innovative Pharmaceutical Company Certification System, which the Ministry of Health and Welfare (MOHW) is pursuing to foster the Korean pharmaceutical industry, is stalling. This is likely due to arguments for and against 'conversion to a rebate scoring system.' Following agreement with the pharmaceutical
- Company
- 'Mounjaro' prescription now available at general hospitals
- by Eo, Yun-Ho Nov 4, 2025 06:10am
- 'Mounjaro,' which ranked No. 1 in global sales, is actively pursuing the prescription area in Korea. According to industry sources, Lilly Korea's dual GIP/GLP-1GIP/GLP-1 receptor agonist Mounjaro (tirzepatide) has passed drug committees (DC) of 66 medical institutes nationwide, including Samsung Medical Center, Kangbuk Samsung Hospital, K
- Opinion
- [Reporter’s View] ‘Selection & Focus’ to foster K-Bios
- by Hwang, byoung woo Nov 4, 2025 06:10am
- The keyword “selection and focus” resurfaced in this year’s National Assembly audit as a core strategy for fostering Korea’s pharmaceutical and bio industry. During the NA audit last month, lawmakers again raised the need for bold investment and full-cycle support for innovative drugs to strengthen Korea’s global competitiveness in
- Company
- Imfinzi reimb discussions at a standstill in Korea
- by Son, Hyung Min Nov 4, 2025 06:10am
- Concerns are mounting over multinational pharmaceutical companies’ market strategies as U.S. President Donald Trump’s Most-Favored-Nation (MFN) drug pricing policy moves toward implementation. If enforced, U.S. drug prices would be pegged to the lowest levels among major advanced markets &8212; raising the risk that Korea’s comparatively low
- Policy
- AI-driven drug R&D key to narrowing gap with global leaders
- by Lee, Jeong-Hwan Nov 4, 2025 06:09am
- The President of the Korea Health Industry Development Institute (KHIDI stressed that Korea must strategically nurture AI and data capabilities to dramatically improve the productivity of AI-based drug R&D and rapidly close the technology gap with advanced pharmaceutical nations. He also revealed a plan to create a KRW 1-trillion mega-fun
- Opinion
- [Desk View] Unsettling relief from pharma tariff agreement
- by Chon, Seung-Hyun Nov 3, 2025 06:09am
- Analysis suggests that the burden of tariffs on the pharmaceutical sector has been significantly alleviated following the settlement of the US-Korea tariff negotiations, which had dragged on for about five months. According to the agreement, the Most Favored Nation (MFN) designation will be granted to synthetic new drugs and biological new d
- Company
- Bispecific antibodies pass reimbursement hurdle
- by Son, Hyung Min Nov 3, 2025 06:09am
- Major bispecific antibody therapies targeting hematologic cancers have successively cleared the first stage of reimbursement. With patients who have failed prior therapies desperately needing new options, attention is focused on whether these new drugs with innovative-mechanism will secure insurance reimbursement. According to industry
- Company
- Olympus to redefine BPH treatment landscape with iTind
- by Hwang, byoung woo Nov 3, 2025 06:09am
- Olympus Korea is moving to reshape the urology market with its benign prostatic hyperplasia (BPH) treatment device, “iTind.” Leveraging the advantages of its non-resection, shape-memory alloy structure, the company is highlighting key features such as sexual function preservation and rapid recovery as it pushes to expand market penetration.
- Company
- Samsung Bioepis wins second trial in Eylea patent dispute
- by Kim, Jin-Gu Nov 3, 2025 06:08am
- Samsung Bioepis has overturned a prior loss and secured victory in the second-instance trial on invalidating the formulation patent for Eylea (aflibercept). The ruling strengthens expectations that commercial sales of its Eylea biosimilar ‘Afilivu’ may resume. According to industry sources on the 31st, the Patent Court on Oct. 30 ruled
- Policy
- Minister Jeong backs INN prescribing for shortage drugs
- by Lee, Jeong-Hwan Nov 3, 2025 06:08am
- Minister of Health and Welfare Eun-kyeong Jeong expressed support for introducing international nonproprietary name (INN) prescribing and expanding substitution dispensing by pharmacists for medicines facing supply instability, as they are national policy tasks. However, she stressed the need to build social consensus given strong opposit
